Abstract Purpose: One of the most relevant aspects in cell death regulation is the signalling of apoptosis by the serine/threonine kinases MAPKs. The aim of this study was to investigate the effects of TNF-α stimulation on MAPK activation, and the pro-or anti-apoptotic role of these kinases in LNCaP and PC3 cells. Material and methods: Treatments were carried out using several TNF-α concentrations, as well as specific pharmacological inhibitors of MAPKs. Apoptosis rates were evaluated by DAPI staining and flow cytometry. MAPK phosphorylation/activation was measured by Western blot. Results: TNF-α induced apoptosis in a dose-dependent manner in LNCaP but not in PC3 cells. The MAPK inhibitors revealed that the apoptotic rate in LNCaP cells increased significantly following p38 inhibition. The kinase inhibitors failed to cause changes in apoptosis in PC3 cells. Conclusions: The potentiation of apoptosis by p38 inhibition points to this kinase as a possible target for the treatment of androgen-dependent prostatic cancer.
Introduction
The role of cytokines in the biology of prostatic cancer is poorly understood. Tumour necrosis factor-α (TNF-α) is a vital member of the multifunctional TNF superfamily with important roles in immunity, cellular remodelling, apoptosis and cell survival [1] . TNF-α is produced by numerous cell types, mainly immune cells but also some non-immune cell types, and several kinds of tumour cells. At present, it has been established that TNF-α displays paradoxical roles in the evolution and treatment of cancer. Lejeune et al. [2] showed that the local administration of high TNF-α doses selectively destroys tumour blood vessels and has powerful anti-cancer actions in melanoma. However several studies revealed that endogenous TNF-α is involved in tumour-cell growth and stromal interactions that facilitate tumour invasion and metastasis [3] . TNF-α can also provide a survival signal for cancer cells and, hence, it has been referred to as a tumour-promoting factor [4] .
One of the most relevant aspects in cell death regulation is the signalling of apoptosis by serine/threonine kinases, a broad category of kinases that includes, among others, the mitogen-activated protein kinases (MAPKs) [5] . The three main members that integrate the MAPK family in mammalian cells are: the stress-activated protein kinase c-Jun NH 2 -terminal kinases (JNK), the stress-activated protein kinase 2 (p38), and the extracellular signal-regulated protein kinases (ERK1/2, p44/p42). Albeit with multiple exceptions, JNK and p38 are generally associated with apoptosis induction, while ERK1/2 are generally associated to mitogenesis, and therefore inversely related to apoptosis [5] . Of note, there are indications proving that components of the MAPK pathways are key mediators of the biological effects of TNF-α, in particular those elicited through TNFRI (TNF receptor I) activation. TNF-α induces apoptosis when it binds to TNFRI, which in turn binds to the TNF receptor-associated death domain (TRADD) molecules (Fig. 1) . TNFRI/TRADD binding results in the activation of a protein cascade (TRAF-2, ASK-1, MEK-4 and JNK) that ends with the activation of the activator protein-1 (AP-1) [6] . Nevertheless, TNFRI/TRADD binding may also elicit anti-apoptotic signals. In fact, MEK-4 phosphorylates p38 which, according to several authors, protects from apoptosis throughout activation of NF-κB. Moreover, NF-κB can also be triggered by TRAF-2 through the receptor interacting protein kinase (RIP) [7] , which is assumed to be one of the main causes of TNF-α resistance [8] . In human colon epithelial cells it was showed that TNF-α caused a dose-dependent ERK activation, and that ERK inhibition down-proinflammatory gene expression [9] .
In preceding publications, we reported the distribution and levels of TNF-α and its receptors [10] , and those of activated and non-activated MAPKs (JNK, p38 and ERKs) [11] as well as the TNF-α transduction pathway [12] in prostatic cancer tissue. In the current study, we attempted to investigate the role of these MAPKs in two cancer prostate cell lines: LNCaP (androgen dependent cells) and PC3 (androgen independent cells) after TNF-α stimulation.
Materials and methods

Cell lines and treatments
Human prostatic cancer cells LNCaP (CRL-1740) and PC3 (CRL-1435), supplied by American Type Culture Collection (ATCC, Rockville, MD), were routinely cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 4.5 g/l glucose, 2 mM L-Glutamine, 10 mM HEPES, 1 mM sodium pyruvate and antibiotics in a humidified 5% CO 2 atmosphere at 37
• C. All cell culture components were obtained from Invitrogen. Both cell lines were tested bimonthly for mycoplasma contamination. For experiments, 24 h before initiation of the treatments the cells were plated at 60% of confluence into 12-well plates. Stock solutions of the kinase inhibitors PD98059, SB203580 and SP600125 were obtained from Calbiochem (Darmstadt, Germany) and prepared in a dimethyl sulfoxide. TNF-α stock solution (50 mg/ml) in distilled water. All these solutions were stored at − 20
• C.
Determination of apoptosis
All cells from a culture were recollected by centrifugation, washed with phosphate-buffered saline (PBS), and resuspended in PBS. To examine chromatin structure, part of the cells were mounted on glass slides; after fixation in 70% (v/v) ethanol, the cells were stained for 20 min at room temperature with 4,6-diamino-2-phenylindole (DAPI) (Serva, Heidelberg, Germany), and examined by fluorescence microscopy. Cells with fragmented chromatin were considered to be apoptotic. To measure DNA content, the remaining cells were incubated for 30 min in PBS containing 0.5 mg/ml RNaseA. After addition of propidium iodide (PI) and permeabilization with 0.1% Nonidet P-40 (at final concentrations of 50 µg/ml and 0.1%, w/v, respectively), the cells were analyzed by flow cytometry, using appropriate colour filters to determine the PI-derived reddish orange fluorescence (emission peak 590 nm). Cells with hypodiploid (sub-G1) DNA content were considered as apoptotic.
Immunoblot assays
To obtain total cellular protein extracts, the cells were collected by centrifugation, washed with phosphate-buffered saline (PBS), and lysed by 5 min of heating at 100
• C followed by sonication in Laemmli buffer containing a protease inhibitor mixture (1 µg/µl leupeptin and 1 µg/µl aprotinin) and phosphatase inhibitors (10 mM sodium fluoride, and 1 mM sodium orthovanadate). The extracts were analyzed by SDS-polyacrilamide gel electrophoresis, blotted onto nitrocellulose membranes (0.2 µm), blocked for 1 h with TBS/5% bovine serum albumin (BSA)/1% Tween-20 (TBST-BSA), and incubated 1 h at room temperature with the primary antibodies in TBST-BSA at 1:1000 dilution. Primary antibodies used were rabbit polyclonal antibodies against human: (1) ERKs (p44/p42 MAPK); (2) . Antibodies were purchased from Santa Cruz Biothecnology (Santa Cruz, California) (antibody 1) and Cell Signalling Technology (Beverly, MA) (antibodies 2-6). For Western blot analysis antichicken α-actin (Amersham, Madrid, Sapin) was also used at the same dilution to examine the relative expression of the other proteins.
After extensive washing with TBS/Tween-20 (TBST), the membranes were incubated with swine anti-rabbit peroxidase-conjugated antibody (Dako, Barcelona, Spain) for 1 h at 1:3000 dilutions in TBST-BSA. After extensive washing, the filters were developed with an enhanced chemiluminescence (ECL) kit, following the procedure described by the manufacturer (Amersham, Buckinghamshire, UK).
Each Western blot analyze was quantified with an automatic image analyzer (Motic Images Advanced version 3.2, Motic China Group Co., China). The data obtained for each experiment represent the means ± SD. Each experiment was repeated six times. The statistical significance between means was assessed by the Students t test at p < 0.001. Figure 2 shows the ability of TNF-α to induce apoptosis in LNCaP and PC3 cells. Treatment of LNCaP cells with TNF-α, at concentrations ranging from 10 to 100 ng/ml, caused a dose-dependent increase in the frequency of apoptotic cells, as determined by chromatin fragmentation (Fig. 2(A) ) and reduced (sub-G1) DNA content ( Fig. 2(C) ). By contrast, no induction of apoptosis was observed in PC3 cells, at all concentrations tested (Fig. 2(B, D) ).
Results
Apoptosis induction
Mitogen activated protein kinase activation
Western blot studies using LNCaP cells revealed that a 72 h treatment with of TNF-α, at concentrations ranging from 10 to 100 ng/ml, resulted in a dose-dependent ERK and JNK activation, as measured by the increase in phosphorylation. On the other hand, increased p38 phosphorylation was only detected at 20 and 50 ng/ml TNF-α (Fig. 3(A, C) ). By contrast, no significant alterations in ERK, JNK and p38 phosphorylation were observed in PC3 cells upon 72 h treatment with TNF-α, at all assayed concentrations (Fig. 3(B, D) ).
Mitogen activated protein kinase inhibition
To elucidate the possible involvement of TNF-α-elicited MAPK activation in apoptosis induction, experiments were carried out using specific pharmacologic inhibitors for each kinase, namely the p38 inhibitor SB203580 (10 µM), the JNK inhibitor SP600125 (10 µM), and the ERK inhibitor PD98059 (20 µM). At these concentrations, the inhibitors were per se innocuous in both LNCaP and PC3 cells (Fig. 4) .
In LNCaP cells, the application of the p38 inhibitor caused a great increase (from one to two-fold, as measured at 48 h of treatment) in the frequency of TNF-α-provoked apoptosis, in comparison to cells treated without the inhibitor (Fig. 4(A) ). Conversely, the JNK inhibitor significantly reduced the frequency of TNF-α-provoked apoptosis (Fig. 4(B) ). The administration of the ERK inhibitor elicited a slight, albeit non-significant rise of apoptotic rate (Fig. 4(C) ).
When PC3 cells were incubated with the MAPK inhibitors, no changes in apoptotic rates were observed (results not shown).
Discussion
The TNF-α transduction pathway has been described as a pathway which bifurcates at the TRAF-2 step, leading to either survival or apoptosis [13] . Among others proteins, TNF-α exerts its function through MAPKs, particularly p38 and JNK [7] .
We have previously reported that the immunoexpression of TNF-α and its receptors (TNFRI and TNFRII) in prostatic cancer samples are increased in comparison with normal prostates [10] . These data agree with those of several studies in leukaemic tissues (non-Hodgkin's lymphoma, acute and chronic myelogenous leukaemia, and chronic lymphocytic leukaemia), in which the presence of high levels of TNF-α and its receptors has been associated with poor prognosis and resistance to therapy [14] . Moreover, we found hyperactivation of the three MAPKs [11] in the same prostatic cancer samples used for the abovementioned TNF-α study. In another work, we examined the components of TNF-α transduction pathway (TRAF-2/ASK-1/MEK-4/JNK/AP-1) that is considered to be a pro-apoptotic pathway [6] , and found that under in vivo conditions this pathway may be inhibited by different factors that interfered with several components of this cascade and that displaced it towards p38 activation at MEK-4 step [12] . When p38 was analyzed in the same samples, we found activation of this MAPK in association with proliferation signals, and not with pro-apoptotic stimuli [11] .
To elucidate whether TNF-α develops in vitro the same responses earlier described in vivo, in the present study we used two human cancer prostate cell lines, namely LNCaP and PC3. Both cell lines are positive for TNFRI (unpublished data). We found that LNCaP developed apoptosis in a TNF-α dose dependent manner, in agreement with the results obtained by Kimura et al. [13] , whereas PC3 showed a resistant phenotype to TNF-α, in agreement with the report of Sintich et al. [15] . Moreover, using Western blot assays we also examined MAPK activation Treatment with the p38 inhibitor SB203580 caused a notable increase in the frequency of apoptosis in LNCaP cell cultures, indicating that p38 exerts an anti-apoptotic action in this cell line. By contrast, no changes in apoptosis were observed in PC3. It is generally assumed that p38 positively regulates cell death by promoting or enhancing apoptosis [7] . However, in the murine fibroblast cell lines L929 and NIH3T3, the p38 pathway seemed to exert a protective function against TNF-induced cell death [7] . Furthermore, mice that underwent deletion of genes encoding TNF-α or its receptor TNFRI were resistant to skin carcinogenesis [16] . In others cases, such as B-cell lymphoproliferative disorders [17] and JAR human choriocarcinoma cell line [18] , p38 appeared to be involved in oncogenesis and high invasion capacity. As a consequence, the authors proposed that p38 inhibition might offer new possibilities to control cancer progression. In agreement with this, the results obtained in the present work using LNCaP cells, and those obtained in our previous in vivo study [11] , suggest that p38 plays an important role in prostatic tumour promotion by TNF-α stimulation, and hence may represent a target for the treatment of prostatic cancer. Of note, LNCaP cells represent a good model of well-differentiated tumour [19] , and as such its behaviour is more comparable to the in vivo tumour condition.
JNK has been described to play a pro-apoptotic action under conditions of TNF-α-induction [6] . TNF-α and its receptors appeared to be overexpressed in prostatic Fig. 4 Effect of MAPK inhibitors on apoptosis induction by TNF-α in LNCap cells. The panels show the frequency of apoptotic cells in untreated cultures (Cont), in cultures treated SB203580 at 10 µM (SB, specific for p38), SP600125 at 10 µM (SP, specific for JNK), and PD98059 at 20 µM (PD, specific for ERKs), either alone or in combination with the indicated concentrations of TNF-α. The inhibitors were applied 6 h before TNF-α, and maintained during the whole treatment. The statistical significance between means ( * ) was assessed by the Student's t-test at p < 0.001 cancer samples [10] , a fact which agrees with the increased apoptotic index reported in these tumour cells [10, 20] . This high apoptotic rate in cancer has been interpreted as an insufficient attempt to counteract the overstimulated cell proliferation. In the present in vitro study, JNK phosphorylation was found to be increased by TNF-α dose-dependent manner in LNCaP cells (but not in PC3 cells), and the rate of apoptosis was reduced by the administration of a specific JNK inhibitor, suggesting that JNK positively regulates apoptosis induction by TNF-α in this cell model. ERK is commonly considered as an anti-apoptotic, cell growth-related kinase, and as such ERK activation favours clinical tumour progression. TNF-α acts as an ERK activator in some cases related to inflammation and cell proliferation. In agreement with this, in the present study ERK phosphorylation was notably increased by TNF-α in LNCaP cells. However, treatment with a specific ERK inhibitor only minimally affected apoptosis, suggesting that ERK activation does not play a significant role in apoptosis regulation in the present experimental situation.
When initially identified, most cancer prostate cancer cells [21] require androgen stimulation for growth. LNCaP have AR mutations and have been shown to be sensitive to antiandrogens and estrogen as well as to androgens. PC3 has an androgen independent growth. These data suggest that our results different could be attributed to androgen influence. Similar differences have been found with other cytokines in prostate cancer cells as IL-6.
Conclusions
In conclusion, in vitro administration of TNF-α causes death by apoptosis in LNCaP prostatic tumour cells, which is accompanied by JNK and p38 MAPK activation However, while JNK seems to positively regulate apoptosis, p38 seems confer cell protection. The behaviour of the p38 signalling pathway observed in vitro in LNCaP cells (a model of welldifferentiated prostatic tumour) agrees with the results observed in vivo studies of prostatic cancer tissue. Hence, down-regulation of p38 activity by specific pharmacological inhibitors may represent a strategy to clinical improve efficacy of TNF-α in androgen-dependent prostatic cancer.
